Search Results

Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies

January , - TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focuse…

FDA Approves Treatment for Patients Newly Diagnosed with Most Common Lymphoma

“The FDA’s decision gives newly diagnosed patients with this aggressive form of lymphoma their first new treatment option in nearly two decades,” says…

Translating molecular profiles into treatment approaches to target disparities in lymphoma

Although many patients with diffuse large lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significa…

Research Highlight: Changing the Landscape of Treatment for Multiple Myeloma (Part 1)

Patients with active MM require therapy; such as chemotherapy, proteasome inhibitors (Bortezomib, Carfilzomib and Ixazomib), immunomodulatory IMiDs (T…

FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder

On January , the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly…

FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma

Chimeric Antigen Receptor (CAR) T is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in . While all prior appro…

Innovations in Blood Cancer Treatment: Navigating CAR T-cell and Bispecific Therapies

Live symposium was held during the Oncology Nursing Society’s (ONS) 50th Annual Congress on April , .

KT1, a novel NK trispecific antibody for the treatment of AML and MDS

New treatments for AML and MDS are urgently needed. We have developed and performed preliminary testing of a novel, , trispecific NK cell engager name…

TCR-like CARs targeting GvL mHAgs for the treatment of post-transplant AML relapse

AML recurrence is a devastating event after . I hypothesize that it could be counteracted through targeting of mHAgs via CARs. I will identify scFVs…

Development of peptide-drug conjugates for the treatment of Chronic Myelomonocytic Leukaemia (CMML)

We are aiming to bring a new treatment option to patients with chronic myelomonocytic leukemia (CMML) by utilising CCL2-drug conjugates that specifica…

The Financial Burden of Blood Cancer Treatment for Working-Aged Adults is Growing

Cancer is one of the most expensive medical conditions to treat in the U.S. As a result, patients, survivors, and caregivers—already challenged by the…

FDA Approves Oral Combo Treatment for Older Adults with Newly Diagnosed AML

“Older adults make up the majority of people diagnosed with AML, and unfortunately many are not eligible for or cannot tolerate intensive chemotherapy…

Creating Safe and Effective Cancer Treatments: FDA Approval Process for Cancer Drugs

By Abby Henry, Oncology Content Manager, PearlPoint Cancer Support

Student trailblazers, part 1: Enterprising teen engineers new way to deliver cancer treatment

One of my favorite things about being Chief Medical Officer of The Leukemia & Lymphoma Society (LLS) is getting to meet so many bright young people co…

Leveraging multispecific antibodies to reshape the treatment landscape of B-cell non-Hodgkin lymphoma

I focus on developing bispecific antibodies (BsAb) for the treatment of lymphoma (). We are testing epcoritamab or mosunetuzumab combinations in fo…

FDA Approves Combination Treatment for Lymphoma Subtype that has Returned or Worsened

WASHINGTON, February , – The U.S. Food and Drug Administration has approved brentuximab vedotin (Adcetris®) to treat adults with large lymphoma, who…

FDA Approves a New Immune-Based Treatment Option for People with Mantle Cell Lymphoma

The FDA continues to expand availability of breakthrough CAR immunotherapy to benefit more blood cancer patientsRYE BROOK, N.Y., May , – The U.S. Fo…

TCR-directed immunotoxins and antibody drug conjugates for the treatment of T cell malignancies

Few treatment options are available for T cell leukemias and lymphomas, collectively called T cell cancers that affect ~, patients worldwide each year…

Autologous CD22 CAR T cell Therapy for the Treatment of non-Hodgkin Lymphoma

CD19 targeting chimeric antigen receptor (CAR) T cell therapies (CAR19) are effective treatments for patients with Lymphoma (NHL), however, the major…

211Astatine-CD123 Radioimmunotherapy for Cancer (Stem) Cell-Directed Treatment of Acute Leukemia

Because acute leukemias are very sensitive to radiation, radioisotopes are ideal payloads to arm antibodies against these , aggressive blood cancers. …

Latest FDA Approval Joins a Torrent of New Treatments for Aggressive Lymphoma Subtype

RYE BROOK, N.Y., July , – The U.S. Food and Drug Administration (FDA) recently approved (Columvi™) to treat adults with diffuse large lymphoma (DLB…

Suggested Reading - Eating Well Through Cancer: Easy Recipes & Recommendations During & After Treatment

: : -0961088880Designed for cancer patients and their family, these recipes focus on foods best tolerated and those to ease the symptoms during trea…

CAR T-Cell Therapy Approved for Initial Treatment of Relapsed Large B-Cell Lymphoma

CLL-1 CAR-T cells and trametinib for the treatment of Ras-mutated CMML and JMML

hypothesize that demonstrating activity of (CLL1CART) cell therapy with or without trametinib in models of chronic myelomonocytic leukemia (CMML) a…

CD7-CAR T cells with PEBL for treatment of children/young adults with relapsed/refractory T-ALL

CD7-CAR T cells with CD7-PEBL represents an innovative technology that enables the production of CAR T cells able to escape the fratricide for the tre…